Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MLN3126 in Healthy Subjects
NCT02447458Phase 1Terminated
- Sponsor
- Takeda
- Start
- Sep 2013
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MLN3126 in inflammatory bowel disease (IBD) (7 arms), sponsored by Takeda. Primary endpoints: Number of Participants That Experience At Least One Treatment-Emergent Adverse Event, Percentage of Participants With Markedly Abnormal Clinical Laboratory Results and 2 more. Started Sep 2013; status: terminated.
02
Drugs
MLN3126
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT02447458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02447458.